8 participants
Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2025-12-30
- Start Date:
- 2020-11-11
- Completion:
- 2023-05-01
Conditions
- Recurrent Chronic Lymphocytic Leukemia
- Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Recurrent Small Lymphocytic Lymphoma
- Refractory Chronic Lymphocytic Leukemia
- Refractory Small Lymphocytic Lymphoma
Interventions
- BIOLOGICAL
- DRUG